Pharmaco - Articles
Gain Valuable Information to: Reduce the attrition rate and increase your speed-to-market through improved collaborative relations Bring higher quality results into your projects through proper partnering techniques Develop a plan to identify and evaluate discovery partners Acquire new negotiation tactics to strengthen your contracts Improve provider performance with proven metric strategies Reduce time gaps due to miscommunication/misinformation Drive discovery to bring your company out on top!
Emerging Drug Discovery Targets from to view this alert on line please go to http://www.leaddiscovery.co.uk/TherapeuticAdvances%20Archive/June%2028th%20emerging%20targets.htm ************************************** "Emerging Drug Discovery Targets" provides a regular summary of some of the most exc…
Rheumatoid arthritis (RA) is one of the more common autoimmune diseases affecting approximately 5 million individuals in the Western world. As described in LeadDiscovery’s state of the art evaluation of rheumatoid arthritis therapeutics (click here), this field is attracting massive interest in the…
Rheumatoid arthritis is one of the more common autoimmune diseases along with multiple sclerosis, type I diabetes and Crohn’s disease. Approximately one in five people in the western world suffer from autoimmune diseases and some estimates indicate that 75% of these are women. In total it is predict…
According to WHO, there are some 130 million diagnosed diabetics in the world, a figure that is predicted to increase to 300 million by 2025. The market for diabetes therapeutics is also rising with global sales reportedly topping $8.1 billion for the 12 months to September 2000, a 19% increase over the previous 12 months (for a full ana…
Pulmonary arterial hypertension (PAH) exists in a rare idiopathic or unexplained form (which occurs in familial and sporadic forms) called idiopathic pulmonary arterial hypertension (IPAH, previously referred to as primary pulmonary hypertension, PPH)) and a relatively common form of secondary pulmo…
The incidence of asthma has dramatically increased over recent years and although currently available treatments are generally effective, patient compliance is currently poor, especially with respect to inhaled treatment. Furthermore, 5% of patients are unresponsive to these treatments and it is this cohort that accounts for a large segment of asthma related healthcare…
PABORD is the first exhibition and conference dedicated to Outsourcing in Research and Development for the Pharmaceutical and Biotechnology industries. With an international line-up of renowned speakers, thiscutting-edge new event is taking place at London's ExCel conference and exhibition venue on September 28th and 29th 2004. Almost 200 companies will be participating at PABORD, Europe's first show that focuses completely on the rapidly expanding trend towards outsourcing in the research and development of new therapeutics. PABORD is extremely well timed, considering how this new trend is having such an increasinglyprofound effect on the…
Glucagon like Peptide-1 (GLP-1) is a gut hormone released after food consumption to stimulate insulin secretion. GLP-1 has a very short half-life due to its degradation by the proteolytic enzyme dipeptidyl peptidase-IV (DPP-IV; CD26) which cleaves peptides after proline residues. Therefore, specific inhibition of DPP-IV is an attractive therapeutic approach to stimulate glucose dependent insulin secretion. In addition to its role in glucose homeostasis, DPP-IV has been implicated in immune disorders, HIV-1 infection and tumor progression a…
In the report 'Biogenerics: Drivers and Resistors of Market Development', Datamonitor evaluates developments in the regulatory environment for biogenerics in the US and EU. The research also analyzes possible market entry strategies and assesses the market potential of biogenerics, and the barriers to companies wishing to enter the industry. Growing demand for biogenerics Despite st…
Off-label usage of drugs and medical devices accounts for a large percentage of profits yet also presents a minefield of potential legal, regulatory, ethical, and financial problems. To make matters worse, the regulatory and legal landscape has become more varied and confusing in recent years as organizations such as the DOJ, the OIG, and more have become involved. Here’s a chance for you to learn everything you need to know about this difficult topic in one easy stop. This conference addresses the following issues (and more): · Understanding and complying with the FDA on off-label issues ·  …
With the advent of powerful, new genomic and proteomic technologies, it should be easy to identify potential biomarkers of safety and efficacy. It should be possible to develop a systematic approach to discover, develop, and validate biomarkers that bridge from pre-clinical evaluations to clin…
DailyUpdates 20th April: Nearly 423,000 new cases of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are expected to have been diagnosed in the seven major pharmaceutical markets in 2003. Despite the high level of pharmaceutical interest, there are significant unmet needs i…
DailyUpdates 11th May: A number of clinical studies including the VIGOR trial have suggested that the NSAID naproxen may reduce the incidence of myocardial infarction. However the gastrointestinal side-effects of naproxen and its ability to exacerbate hypertension preclude its use in at-r…
DailyUpdates 10th May: Last week European regulators affirmed the safety of Celebrex; good news for Pfizer continues with the emergence of data from the PACES trials reporting that, compared to acetaminophen, Celebrex is both preferred by patients and is of greater efficacy. Osteoarthritis is characterized by the degeneration of the articular cartilage and is the most prevalent form of arthritis, affecting 10% of the population, equating to a patient population of over 73 million people in the seven major pharmaceutica…
Pharmaceutical Education Associates Presents: Signal Detection throughout the Product Life Cycle – The Park Hyatt at the – Pharmaceutical companies have been tracking adverse events, drug reactions and drug safety issues for years. Now, the most successful companies are implementing innovative methods and ways of data mining into complex, multi-faceted databases to proactively identify and analyze signals that occur not only in post-marketing surveillance, but in all phases of drug development as well. Even the regulatory agencies like the FDA are developing new recommendations for analyzing data that will help in identifying signals earlier – even in…
Medicines wants to know:"Why has there been a decline in interest in science, maths and technology?" Dr Philip Wright said: Well there's not really any single explanation about why there's been a decline what we're most concerned about actually are chemistry courses and attracting young people to take part. In part because somehow we're missing the excitement of practical science that's the thing that attracted me to science. In chemistry we're seeing a situation where over 70% of GCSE chemistry classes are taken by teachers without a chemistry degree. Which is a bit worrying. Somehow we have to attract students to do chemistry degrees and then some of those graduates need to teaching. Sasha wan…
Emerging Drug Discovery Targets from LeadDiscovery 6th May 2004 to view this alert on line please go to http://www.leaddiscovery.co.uk/TherapeuticAdvances%20Archive/May%206th%20emerging%20targets.htm ************************************** "Emerging Drug Discovery Targets" provides a twice monthly su…
DailyUpdates 5th May: As the battle lines are drawn up between gabapentin and its generic equivalents, research published by Turkish researchers suggests that the first-line use of these therapeutics in the treatment of neuropathic pain associated with spinal cord injury will represent one battle in the war between Pfizer and its competitors. Approximately 26 million patients worldwide (10 million in the ) suffer from some form of neuropathic pain…